Compare Apollo Global Management Ord Shs (APO) vs Crispr Therapeutics AG (CRSP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Apollo Global Management Ord Shs vs Crispr Therapeutics AG — how do they compare? Apollo Global Management Ord Shs trades at $140.8 (market cap $82.84B), while Crispr Therapeutics AG trades at $54.52 (market cap $5.23B). The key difference: Apollo Global Management Ord Shs is far larger — about 15.8× Crispr Therapeutics AG's market cap, and Apollo Global Management Ord Shs pays a 1.6% dividend while Crispr Therapeutics AG pays none. Which is the better fit depends on your goals.
| APO | CRSP | |
|---|---|---|
Market Cap | $82.84B | $5.23B |
Sector | Financials | Health |
52-Week High | $152.70 | $76.78 |
52-Week Low | $100.30 | $44.34 |
Enterprise Value | -$168.65B | $3.65B |
Dividend Yield | 1.6% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Apollo Global Management (APO) trades at $132.02, up 3.59% in 24 hours, with strong technical momentum as it approaches resistance near $134. The company reported mixed Q2 2026 earnings, missing EPS estimates but achieving record fee-related earnings of $785 million (Seeking Alpha, August 4, 2026). Fundamentals show robust revenue growth, with 2025 revenue at $32.05 billion, though net income margins have declined to 5.22% from prior peaks.
Outlook remains positive with an 82% analyst buy rating and a $151.50 price target, but risks include high P/E of 49.92 and exposure to private credit market volatility. Recent news highlights strategic AI infrastructure deals, such as a $2.6 billion partnership with Yankee Global Enterprises (Business Wire, August 11, 2026), supporting long-term growth amid competitive pressures.
CRISPR Therapeutics (CRSP) trades at $53.51, down slightly by 0.02% today. The stock shows bullish technical signals with strong support at $53 and resistance at $54. Fundamentally, the company reports widening losses with a net income margin of -4,101.26% in 2025, though Q2 2026 earnings beat expectations. Analyst sentiment remains positive with a consensus price target of $82.67, driven by robust CASGEVY sales growth and pipeline advancements.
Outlook: CRSP offers significant upside potential from gene-editing therapeutics, but high cash burn and negative profitability pose risks. Investment appeal hinges on successful clinical trials and market expansion of approved therapies, balanced against financial sustainability concerns in a competitive biotech landscape.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Apollo Global Management Ord Shs
Apollo Global Management Inc is an alternative investment manager. It serves various sectors such as chemicals, manufacturing and industrial, natural resources, consumer and retail, consumer services, business services, financial services, leisure, and media and telecom and technology. The company operates in three business segments that are Private Equity, Credit, and Real Assets. It generates maximum revenue from the Credit segment in the form of fees. The credit segment primarily invests in non-control corporate and structured debt instruments including performing, stressed and distressed instruments across the capital structure. It also includes Corporate Credit
Read more on APO →About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →
